dihexa clinicaltrials.gov Evidence out, ideology in. The FDA's quiet peptide pivot has nothing to do with the data and everything to do with whose side the regulator is choosing. On April 15, 2026, the Dihexa: Off FDA Category 2,

In a Phase II readout released in August 2022, the pharma touted a 15.6% drop in body weight in patients taking CagriSema, versus 5.1% in comparators on semaglutide alone and 8.1% in patients treated with only cagrilintide

(December 2000)

DSIP cortisol-lowering effects could theoretically interact with corticosteroids or medications affecting the HPA axis

BPC 157 treatment led to the upregulation of Egr1, Akt1, Kras, Src, Foxo, Srf, Vegfr2, Nos3, and Nos1 and the downregulation of Nos2 and Nfkb compared with untreated rats

As you may (or may not) recall from your high school and college physics courses, heat loss can occur through a variety of mechanisms including conduction, convection, evaporation, and radiation (Table 2) An elderly patient who had an unwitnessed fall with a prolonged downtime can experience conductive heat loss with the floor